{
    "hands_on_practices": [
        {
            "introduction": "In Autosomal Dominant Polycystic Kidney Disease (ADPKD), an individual inherits one faulty copy of a gene like $\\mathrm{PKD1}$, yet only a small fraction of their millions of kidney tubules develop into cysts. This practice explores the \"two-hit\" hypothesis, which provides a powerful explanation for this phenomenon. By modeling the chance of a spontaneous \"second hit\" in a single cell lineage, you will quantitatively grasp how these rare somatic events are the crucial triggers for cyst initiation, leading to the characteristic mosaic pattern of the disease .",
            "id": "4801047",
            "problem": "A patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) carries a germline heterozygous variant in the polycystin-1 gene ($\\mathrm{PKD1}$). In the somatic second-hit model of cyst initiation, a focal tubular epithelial cell can initiate a cyst when a subsequent somatic event (e.g., a mutation or loss of heterozygosity (LOH)) functionally inactivates the remaining wild-type allele. Consider a single tubular epithelial cell lineage that undergoes $N=10^{6}$ mitotic divisions over time. Suppose the per-division probability of a somatic second hit that inactivates the wild-type allele is $\\mu=1\\times 10^{-7}$, and assume independence of divisions with a constant per-division risk across the lineage.\n\nUsing first principles of probability for independent Bernoulli trials, derive from the complement rule the probability $P$ that at least one effective second hit occurs somewhere in this lineage. Then evaluate $P$ numerically for the given $\\mu$ and $N$. Express your answer as a decimal fraction and round to four significant figures. Finally, explain conceptually (not as part of the numerical answer) how this focal probability relates to mosaic cyst initiation in the context of a germline heterozygous $\\mathrm{PKD1}$ variant.",
            "solution": "The problem statement has been critically validated and is deemed valid. It is scientifically grounded in the accepted two-hit model of cystogenesis in Autosomal Dominant Polycystic Kidney Disease (ADPKD), well-posed with all necessary information provided, and objective in its formulation. The problem asks for the derivation and calculation of a probability based on a series of independent Bernoulli trials and a conceptual explanation of the result in a biological context.\n\nThe problem can be modeled as a sequence of $N$ independent Bernoulli trials, where each trial corresponds to a single mitotic division of a cell in the lineage. A \"success\" is defined as the occurrence of a somatic second hit that inactivates the wild-type $\\mathrm{PKD1}$ allele. The probability of success in any single trial is given as $\\mu$.\n\nLet $S_i$ be the event of a second hit occurring during the $i$-th division, for $i = 1, 2, \\dots, N$.\nThe probability of this event is $P(S_i) = \\mu$.\nThe event that no second hit occurs during the $i$-th division is the complement event, denoted $S_i^c$. Its probability is $P(S_i^c) = 1 - \\mu$.\n\nThe problem asks for the probability $P$ that at least one effective second hit occurs somewhere in the lineage of $N$ divisions. This can be expressed as the probability of the union of all success events:\n$$P = P(S_1 \\cup S_2 \\cup \\dots \\cup S_N)$$\nCalculating this directly is cumbersome. It is more straightforward to use the complement rule, as requested by the problem. The complement of \"at least one hit\" is \"zero hits\".\nLet $A$ be the event that at least one hit occurs in $N$ divisions. The complement event, $A^c$, is that no hits occur in any of the $N$ divisions.\n$$P(A) = 1 - P(A^c)$$\nThe event $A^c$ corresponds to the intersection of the events where no hit occurred in each individual division:\n$$A^c = S_1^c \\cap S_2^c \\cap \\dots \\cap S_N^c$$\nSince the divisions are assumed to be independent events, the probability of the intersection is the product of the individual probabilities:\n$$P(A^c) = P(S_1^c) \\times P(S_2^c) \\times \\dots \\times P(S_N^c) = \\prod_{i=1}^{N} P(S_i^c)$$\nSince $P(S_i^c) = 1 - \\mu$ for all $i$, this simplifies to:\n$$P(A^c) = (1 - \\mu)^N$$\nSubstituting this back into the complement rule, we obtain the desired expression for $P$:\n$$P = 1 - (1 - \\mu)^N$$\nThis is the derived probability that at least one effective second hit occurs in the lineage.\n\nNow, we evaluate $P$ numerically using the given values:\nNumber of divisions, $N = 10^6$.\nPer-division probability of a second hit, $\\mu = 1 \\times 10^{-7}$.\n\nSubstituting these values into the derived formula:\n$$P = 1 - (1 - 1 \\times 10^{-7})^{10^6}$$\n$$P = 1 - (1 - 0.0000001)^{1000000}$$\n$$P = 1 - (0.9999999)^{1000000}$$\nCalculating the value of the term $(0.9999999)^{1000000}$:\n$$(0.9999999)^{1000000} \\approx 0.90483736$$\nTherefore, the probability $P$ is:\n$$P \\approx 1 - 0.90483736 = 0.09516264$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $9$, $5$, $1$, and $6$. The fifth significant figure is $2$, which is less than $5$, so we do not round up.\n$$P \\approx 0.09516$$\n\nConceptually, this probability $P \\approx 0.09516$ (or about $9.5\\%$) represents the risk that a *single* tubular epithelial cell lineage, starting from a cell with a germline $\\mathrm{PKD1}$ mutation, will give rise to a cyst-initiating cell over the course of $10^6$ divisions. This risk for a single lineage is relatively low.\n\nHowever, the human kidney is composed of millions of renal tubules, each containing thousands of such epithelial cells. Each of these cells can be considered the progenitor of a distinct lineage, running an independent \"probabilistic experiment\". If there are, for example, $M$ such independent lineages in the kidneys, the probability that *at least one* of them initiates a cyst is $1 - (1-P)^M$. Given that $M$ is a very large number, this probability approaches $1$ (certainty), even though $P$ itself is small. This explains the high penetrance of the diseaseâ€”why individuals with a germline $\\mathrm{PKD1}$ mutation almost invariably develop numerous cysts. The cysts arise from focal, sporadic second-hit events, meaning the kidney tissue becomes a \"mosaic\" of a vast majority of cells that are heterozygous at the $\\mathrm{PKD1}$ locus (one hit) and a small number of clonal cell populations that are functionally null for $\\mathrm{PKD1}$ (two hits) and which go on to form the cysts. This calculated focal probability is the fundamental unit of risk that, when scaled up to the level of the entire organ, accounts for the clinical phenotype of ADPKD.",
            "answer": "$$\\boxed{0.09516}$$"
        },
        {
            "introduction": "The clinical endpoint of greatest concern in ADPKD is the progressive loss of kidney function, measured by the estimated Glomerular Filtration Rate (eGFR). This practice uses a simplified linear model to illustrate how therapies that slow the rate of disease progression can significantly delay the onset of end-stage kidney disease. By calculating the time gained from a specific therapeutic intervention, you will appreciate the profound clinical impact of treatments that modify the natural history of ADPKD .",
            "id": "4321953",
            "problem": "Autosomal Dominant Polycystic Kidney Disease (ADPKD) is characterized by progressive cyst expansion that compresses normal parenchyma, leading to a decline in the estimated glomerular filtration rate (eGFR). In population-based longitudinal analyses, the trajectory of eGFR over time can be approximated as a deterministic linear decline under stable conditions. End-stage kidney disease (ESKD) is conventionally defined as the point at which the eGFR first reaches $15 \\text{ ml/min}/1.73 \\text{ m}^2$.\n\nConsider a patient with ADPKD whose untreated eGFR decline can be modeled as a constant slope of $-3.7 \\text{ ml/min}/1.73 \\text{ m}^2/\\text{year}$. A vasopressin V2 receptor antagonist (tolvaptan) therapy is initiated when the eGFR is $60 \\text{ ml/min}/1.73 \\text{ m}^2$, and for the purpose of this model, its effect is to reduce the magnitude of the decline by $1.0 \\text{ ml/min}/1.73 \\text{ m}^2/\\text{year}$ from the time of initiation onward, with no other changes in trajectory or acute effects. Assume that, both with and without therapy, the eGFR evolves linearly with time and that the first passage to $15 \\text{ ml/min}/1.73 \\text{ m}^2$ defines the onset of ESKD.\n\nUsing these assumptions and starting from the basic definition that a linear trajectory of eGFR can be written as $G(t)=G_{0}+m\\,t$ with constant slope $m<0$ and initial value $G_{0}$ at $t=0$, compute the expected delay to ESKD attributable to tolvaptan therapy when initiated at $G_{0}=60 \\text{ ml/min}/1.73 \\text{ m}^2$. Express your final answer in years and round to three significant figures.",
            "solution": "The problem asks for the delay to the onset of end-stage kidney disease (ESKD) due to a specific therapy in a patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD). The progression of the disease is modeled as a linear decline in the estimated glomerular filtration rate (eGFR).\n\nFirst, we formalize the model. The eGFR, denoted by $G(t)$, at a time $t$ in years is given by the linear equation:\n$$G(t) = G_{0} + m \\cdot t$$\nwhere $G_0$ is the initial eGFR at $t=0$, and $m$ is the constant rate of decline (the slope), which is negative ($m<0$).\n\nThe problem defines ESKD as the point when the eGFR first reaches $G_f = 15 \\text{ ml/min}/1.73 \\text{ m}^2$. We are given that the therapy is initiated when the eGFR is $G_0 = 60 \\text{ ml/min}/1.73 \\text{ m}^2$. We can calculate the time $t$ required to reach ESKD by setting $G(t) = G_f$ and solving for $t$:\n$$G_f = G_0 + m \\cdot t$$\n$$t = \\frac{G_f - G_0}{m}$$\n\nWe need to analyze two scenarios: one without therapy (untreated) and one with therapy (treated).\n\nScenario 1: Untreated Patient\nIn the untreated case, the slope of eGFR decline is given as $m_{untreated} = -3.7 \\text{ ml/min}/1.73 \\text{ m}^2/\\text{year}$.\nThe time to reach ESKD, $t_{untreated}$, is calculated using the formula derived above:\n$$t_{untreated} = \\frac{G_f - G_0}{m_{untreated}}$$\nSubstituting the given values:\n$$t_{untreated} = \\frac{15 - 60}{-3.7} = \\frac{-45}{-3.7} = \\frac{45}{3.7} \\, \\text{years}$$\n\nScenario 2: Patient on Tolvaptan Therapy\nThe therapy is stated to reduce the magnitude of the eGFR decline by $1.0 \\text{ ml/min}/1.73 \\text{ m}^2/\\text{year}$. The magnitude of the untreated decline is $|m_{untreated}| = |-3.7| = 3.7 \\text{ ml/min}/1.73 \\text{ m}^2/\\text{year}$.\nThe new magnitude of decline with therapy is $3.7 - 1.0 = 2.7 \\text{ ml/min}/1.73 \\text{ m}^2/\\text{year}$.\nTherefore, the new slope of eGFR decline for the treated patient is $m_{treated} = -2.7 \\text{ ml/min}/1.73 \\text{ m}^2/\\text{year}$.\n\nThe time to reach ESKD for the treated patient, $t_{treated}$, is calculated using the same formula but with the new slope:\n$$t_{treated} = \\frac{G_f - G_0}{m_{treated}}$$\nSubstituting the values:\n$$t_{treated} = \\frac{15 - 60}{-2.7} = \\frac{-45}{-2.7} = \\frac{45}{2.7} \\, \\text{years}$$\n\nCalculating the Delay to ESKD\nThe delay to ESKD attributable to the therapy is the difference between the time to reach ESKD with therapy and the time to reach ESKD without therapy:\n$$\\Delta t = t_{treated} - t_{untreated}$$\nSubstituting the expressions for $t_{treated}$ and $t_{untreated}$:\n$$\\Delta t = \\frac{45}{2.7} - \\frac{45}{3.7}$$\nWe can factor out the common term $G_f - G_0 = -45$:\n$$\\Delta t = (G_f - G_0) \\left( \\frac{1}{m_{treated}} - \\frac{1}{m_{untreated}} \\right)$$\n$$\\Delta t = (-45) \\left( \\frac{1}{-2.7} - \\frac{1}{-3.7} \\right) = 45 \\left( \\frac{1}{2.7} - \\frac{1}{3.7} \\right)$$\nTo compute the numerical value:\n$$t_{untreated} = \\frac{45}{3.7} \\approx 12.162162... \\, \\text{years}$$\n$$t_{treated} = \\frac{45}{2.7} = \\frac{450}{27} = \\frac{50}{3} \\approx 16.666666... \\, \\text{years}$$\nThe delay is:\n$$\\Delta t = 16.666666... - 12.162162... = 4.5045045... \\, \\text{years}$$\nThe problem requires the final answer to be rounded to three significant figures. The fourth significant figure is $4$, so we round down.\n$$\\Delta t \\approx 4.50 \\, \\text{years}$$",
            "answer": "$$\\boxed{4.50}$$"
        },
        {
            "introduction": "Effectively managing ADPKD involves identifying patients at the highest risk of rapid progression who are most likely to benefit from therapy. This exercise puts you in the role of a clinician applying the Mayo imaging classification, a cornerstone of modern ADPKD risk stratification. You will use total kidney volume (TKV), a key structural biomarker, to calculate a patient's risk class, directly linking organ-level anatomical changes to clinical decision-making .",
            "id": "4321955",
            "problem": "An adult patient with Autosomal Dominant Polycystic Kidney Disease (ADPKD) presents for imaging-based risk stratification. The kidneys show bilaterally enlarged, diffusely cystic parenchyma without segmental sparing, consistent with a typical ADPKD phenotype appropriate for application of the Mayo imaging classification. The following measurements are obtained:\n- Total kidney volume (TKV): 950 mL\n- Standing height: 1.70 m\n- Age: 35 years\n\nStarting from core definitions and well-tested facts, construct a TKV-based risk classification using the Mayo imaging classification for typical ADPKD and compute the height-adjusted total kidney volume (HtTKV). Encode the assigned Mayo subclass (typical classes $1\\mathrm{A}$, $1\\mathrm{B}$, $1\\mathrm{C}$, $1\\mathrm{D}$, $1\\mathrm{E}$) numerically as $1 \\rightarrow 1\\mathrm{A}$, $2 \\rightarrow 1\\mathrm{B}$, $3 \\rightarrow 1\\mathrm{C}$, $4 \\rightarrow 1\\mathrm{D}$, $5 \\rightarrow 1\\mathrm{E}$. \n\nExpress HtTKV in $\\mathrm{mL/m}$ and round your HtTKV result to four significant figures. Report your final answer as a two-entry row matrix using the LaTeX $\\mathrm{pmatrix}$ environment, with the first entry equal to the rounded HtTKV (in $\\mathrm{mL/m}$, but do not include units in the matrix) and the second entry equal to the numerical code for the Mayo subclass.",
            "solution": "The problem statement is evaluated for validity before proceeding to a solution.\n\n**Step 1: Extract Givens**\n- Patient diagnosis: Autosomal Dominant Polycystic Kidney Disease (ADPKD), typical phenotype\n- Total kidney volume (TKV): 950 mL\n- Standing height: 1.70 m\n- Age: 35 years\n- Task: Compute height-adjusted total kidney volume (HtTKV) and determine the Mayo imaging classification subclass.\n- Encoding for Mayo subclass: $1 \\rightarrow 1\\mathrm{A}$, $2 \\rightarrow 1\\mathrm{B}$, $3 \\rightarrow 1\\mathrm{C}$, $4 \\rightarrow 1\\mathrm{D}$, $5 \\rightarrow 1\\mathrm{E}$.\n- Rounding requirement: HtTKV must be rounded to four significant figures.\n- Final answer format: A two-entry row matrix containing the rounded HtTKV and the numerical Mayo subclass code.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem is scientifically grounded. The Mayo imaging classification for ADPKD is a well-established, validated tool used in clinical practice and research for risk stratification, based on the work of Irazabal et al. (2015, J Am Soc Nephrol). The variables (TKV, height, age) and their use in calculating HtTKV are central to this classification. The provided clinical data are plausible for an adult with ADPKD. The problem is well-posed, providing all necessary information to compute a unique solution. The language is objective and precise. The problem is therefore deemed valid.\n\n**Step 3: Verdict and Action**\nThe problem is valid. A complete solution will be provided.\n\n**Solution Derivation**\n\nThe primary objective is to classify the patient's disease severity using the Mayo imaging classification for typical ADPKD. This requires two main steps: first, calculating the height-adjusted total kidney volume (HtTKV), and second, comparing this value against age-specific thresholds to determine the risk subclass.\n\n1.  **Calculation of Height-Adjusted Total Kidney Volume (HtTKV)**\n    The HtTKV is a normalized metric that accounts for variations in kidney size due to patient stature. It is defined as the total kidney volume divided by the patient's height.\n\n    The given values are:\n    - Total Kidney Volume, TKV = $950 \\text{ mL}$\n    - Height, $h = 1.70 \\text{ m}$\n\n    The formula for HtTKV is:\n    $$\n    \\mathrm{HtTKV} = \\frac{\\mathrm{TKV}}{h}\n    $$\n    Substituting the given values into the formula:\n    $$\n    \\mathrm{HtTKV} = \\frac{950 \\text{ mL}}{1.70 \\text{ m}} \\approx 558.8235... \\text{ mL/m}\n    $$\n    The problem requires rounding the HtTKV to four significant figures.\n    $$\n    \\mathrm{HtTKV}_{\\text{rounded}} = 558.8 \\text{ mL/m}\n    $$\n\n2.  **Determination of Mayo Imaging Classification Subclass**\n    The Mayo imaging classification stratifies patients with typical ADPKD into five risk classes ($1\\mathrm{A}$, $1\\mathrm{B}$, $1\\mathrm{C}$, $1\\mathrm{D}$, $1\\mathrm{E}$) based on their HtTKV and age. These classes correspond to predicted annual rates of TKV growth. For a patient of a given age, there are specific HtTKV thresholds that define the boundaries between these classes.\n\n    The patient's age is $35 \\ \\mathrm{years}$. The established HtTKV thresholds (in $\\mathrm{mL/m}$) for this age are:\n    -   Class $1\\mathrm{A}$: HtTKV $< 321$ (Corresponds to predicted TKV growth $< 1.5\\%$/year)\n    -   Class $1\\mathrm{B}$: $321 \\le$ HtTKV $< 512$ (Corresponds to predicted TKV growth $1.5\\%$ to $3.0\\%$/year)\n    -   Class $1\\mathrm{C}$: $512 \\le$ HtTKV $< 793$ (Corresponds to predicted TKV growth $3.0\\%$ to $4.5\\%$/year)\n    -   Class $1\\mathrm{D}$: $793 \\le$ HtTKV $< 1208$ (Corresponds to predicted TKV growth $4.5\\%$ to $6.0\\%$/year)\n    -   Class $1\\mathrm{E}$: HtTKV $\\ge 1208$ (Corresponds to predicted TKV growth $> 6.0\\%$/year)\n\n    The patient's calculated HtTKV is $558.8 \\text{ mL/m}$. We compare this value to the thresholds:\n    The value $558.8$ satisfies the inequality $512 \\le 558.8 < 793$.\n    Therefore, the patient is classified into Mayo Class $1\\mathrm{C}$.\n\n3.  **Encoding the Subclass and Final Answer Formulation**\n    The problem specifies a numerical encoding scheme for the Mayo subclasses: $1 \\rightarrow 1\\mathrm{A}$, $2 \\rightarrow 1\\mathrm{B}$, $3 \\rightarrow 1\\mathrm{C}$, $4 \\rightarrow 1\\mathrm{D}$, $5 \\rightarrow 1\\mathrm{E}$.\n    Since the patient's classification is Class $1\\mathrm{C}$, the corresponding numerical code is $3$.\n\n    The final answer is to be presented as a two-entry row matrix with the rounded HtTKV as the first entry and the numerical subclass code as the second.\n    -   First entry: $558.8$\n    -   Second entry: $3$\n\n    The resulting matrix is $\\begin{pmatrix} 558.8 & 3 \\end{pmatrix}$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n558.8 & 3\n\\end{pmatrix}\n}\n$$"
        }
    ]
}